Baseline patient demographic and clinical characteristics

PlaceboDupilumab 200mg every 2weeksPlaceboDupilumab 300mg every 2weeksOverall population
Age years48.2±15.647.9±15.348.2±14.747.7±15.647.9±15.3
Female198 (62.5)387 (61.3)218 (67.9)394 (62.2)1197 (62.9)
BMI kg·m−229.76±7.2529.05±6.5229.21±6.9529.07±6.6829.20±6.77
Pre-bronchodilator FEV1 L1.76±0.611.78±0.621.75±0.571.78±0.601.78±0.60
Pre-bronchodilator FEV1% predicted58.43±13.2258.38±13.5258.35±13.8758.51±13.5258.43±13.52
FEV1 reversibility %25.06±18.7627.39±22.7926.45±17.6525.73±23.7926.29±21.73
Exacerbations in past year2.07±1.582.07±2.662.31±2.072.02±1.862.09±2.15
High-dose ICS use172 (54.3)317 (50.2)167 (52.0)323 (51.0)979 (51.5)
ACQ-5# score2.71±0.732.76±0.802.77±0.772.77±0.762.76±0.77
Biomarker levels
 Blood eosinophil count cells·µL−1370±338349±345391±419351±369360±366
FeNO ppb34.47±28.5434.45±34.9138.39±38.0034.01±29.7434.97±32.85

Data are presented as n, mean±sd or n (%). Baseline blood eosinophil data were missing for one randomised patient receiving dupilumab 200 mg every 2 weeks and one randomised patient receiving placebo 2 mL/300 mg every 2 weeks and were excluded from efficacy analyses. BMI: body mass index; FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroid; ACQ-5: five-item Asthma Control Questionnaire; FeNO: fractional exhaled nitric oxide. #: ACQ-5 is a patient-reported measure of the adequacy of asthma control and change in asthma control that occurs either spontaneously or as a result of treatment. Higher scores indicate less control; a global score of 0–6 is calculated.